Loading...
Despite the recent advances in all-oral treatment regimens for patients with hepatitis C virus (HCV) genotype 1 infection, treatment options for patients with advanced kidney disease are still limited.
In an industry-funded, phase III study, investigators randomized 224 patients with stage 4 or 5 chronic kidney disease with or without hemodialysis and HCV genotype 1 infection to receive grazoprevir (100 mg; an NS3/4A protease inhibitor) and elbasvir (50 mg; an NS5A inhibitor) in a single pill or placebo daily for 12 weeks. An additional 11 patients received treatment in an open-label fashion for purposes of intensive pharmacokinetic analysis. Of all 235 patients, 80% were treatment-naive, 6% had cirrhosis, 46% were African-American, and 76% …